Pioneering study in Immunity: TBX1 restrains autoimmunity after myocardial infarction

In Immunity, the lab co-led the discovery of a TBX1-driven lymphatic-endothelial program that suppresses autoimmunity and inflammation following heart attack. The findings define a time-synchronized window in which early, transient immunomodulation could improve recovery while avoiding the side effects of long-term immunosuppression. Read the paper. · Texas Heart Institute press release.